Kolaczynska KE

Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.

8 papers · ORCID

ArticlePsychedelics

Receptor interaction profiles of 4-alkoxy-2,6-dimethoxyphenethylamines (Ψ derivatives) and related amphetamines.

Kolaczynska KE, Trachsel D, Hoener MC +2

Europe PMC2025
ArticlePsilocybin

<i>In vitro</i> and <i>in vivo</i> metabolism of psilocybin's active metabolite psilocin.

Thomann J, Kolaczynska KE, Stoeckmann OV +7

Europe PMC2024
ArticlePsilocybin

Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants.

Holze F, Becker AM, Kolaczynska KE +2

Europe PMC2023
ArticleDMT

Liquid chromatography-tandem mass spectrometry method for the bioanalysis of N,N-dimethyltryptamine (DMT) and its metabolites DMT-N-oxide and indole-3-acetic acid in human plasma.

Luethi D, Kolaczynska KE, Vogt SB +4

Europe PMC2022
ArticlePsilocybin

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.

Holze F, Ley L, Müller F +10

Europe PMC2022
ArticleMescaline

Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines.

Kolaczynska KE, Luethi D, Trachsel D +2

Europe PMC2021
ArticlePsilocybin

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.

Becker AM, Holze F, Grandinetti T +8

Europe PMC2022
ArticlePsilocybin

Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin's main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma.

Kolaczynska KE, Liechti ME, Duthaler U

Europe PMC2021